P&G launches Febreze pet-odor products
CINCINNATI Procter & Gamble has launched two new products to eliminate pet-related odor under the Febreze brand, the company announced Tuesday.
The products include an odor-neutralizing candle, Febreze Candles Pet Odor Eliminator, and Febreze NOTICEables Pet Odor Eliminator, a scented oil.
The company said that while other air fresheners cover up pet odors, its new products eliminate the odors from the air and deliver a fresh scent.
“The success of Febreze Fabric Refresher and Air Effects Pet Odor Eliminator has led the brand to extend freshness to more pet homes across the country,” Febreze brand manager Scott Beal said. “The addition of Febreze Candles and Febreze NOTICEables Pet Odor Eliminator will provide pet owners freshness and odor elimination benefits in a broader and more versatile line.”
FDA approves Mylan’s generic Sular
PITTSBURGH The Food and Drug Administration has granted final approval to a Mylan hypertension drug, the company has announced.
The drug, nisoldipine extended release, is a generic version of Sciele Pharma’s drug Sular ER. The drug will be available in 20 mg, 30 mg and 40 mg strengths.
Sular had sales of about $94 million in the year ended March 31, according to Mylan. The ‘741 patent that protected Sular expired June 8.
FDA adopts new policies for advisory committees
WASHINGTON The Food and Drug Administration announced Monday that it has adopted several improved policies and procedures to strengthen management of FDA advisory committees.
The improvements include stricter limits on financial conflicts of interest for committee members, improved voting procedures and improved disclosure processes related to advisory committee members and issues considered at their meetings.
Prior to each meeting, FDA staff will screen advisory committee members for potential financial conflicts of interest, such as grants, stock holdings and contracts with any company the committee’s recommendations would affect. The FDA is instituting a cap of $50,000 as the maximum financial interest an adviser may have in all companies a particular meeting might affect. Advisers with financial interests more than $50,000 will be excluded from the meeting. Advisers with interests of less than $50,000 may receive a waiver, but only if the FDA staff determine a need for their expertise.
The agency will also post briefing materials that committee members receive on the FDA’s Web site at least two days before the meeting.
In another improvement, the agency has issued guidelines regarding how committees vote on issues to avoid even the perception of vote manipulation, recommending that all members vote simultaneously.
The FDA also proposed new criteria to determine when it should refer a matter to a committee. In some instances, the law would require it. In others, the agency would consider the new criteria when deciding whether to refer a matter.